Table 2.
Comparison of the predictive value of an end-of-therapy 18F-FDG PET scan versus CT scan for relapse in NHL
| Series | No of HL cases | N | PET+ and CT+ | PET+ and CT- | PET- and CT+ | PET- and CT- | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Relapse | Total | Relapse | Total | Relapse | Total | Relapse | Total | Relapse | ||
| De Wit et al 18 | 17 | 34 | 8 | 16 | 7 | 1 | 1 | 16 | 0 | 1 | 0 |
| Jerusalem et al 19 | 19 | 54 | 14 | 5 | 5 | 1 | 1 | 19 | 5 | 29 | 3 |
| Zinzani et al 20 | 13 | 44 | 14 | 13 | 13 | 0 | 0 | 24 | 1 | 7 | 0 |
| Mikhaeel et al 21 | 0 | 33 | 11 | 5 | 5 | 1 | 1 | 12 | 2 | 15 | 3 |
| Spaepen et al 22 | 0 | 93 | 37 | 12 | 12 | 14 | 14 | 14 | 1 | 53 | 10 |
| Kostakoglu et al 24 | 10 | 23 | 11 | 1 | 0 | 5 | 5 | 1 | 1 | 16 | 5 |
| Zinzani et al 26 | 10 | 75 | 14 | 11 | 10 | 5 | 4 | 30 | 0 | 29 | 0 |
| Kumar et al 23 | 0 | 18 | 7 | 6 | 6 | 0 | 0 | 3 | 0 | 9 | 1 |
| Reinhardt et al 27 | 34 | 101 | 28 | 24 | 20 | 0 | 0 | 57 | 8 | 20 | 0 |
| Han et al 29 | 0 | 48 | 7 | 7 | 1 | 2 | 0 | 9 | 2 | 30 | 4 |
| Total | 127 | 523 | 151 | 100 | 79 | 29 | 26 | 185 | 20 | 209 | 26 |
| Relapse rate | 29% | 79% | 90% | 11% | 12% | ||||||
Abbreviations: 18F-FDG PET: 18Flourine-Flourodeoxyglucose Positron Emission Tomography, CT: Computed Tomography, NHL: Non-Hodgkin Lymphoma, HL: Hodgkin Lymphoma.